Big Pharma
24 June 2025 Trio have worked together for several years at different firms, bringing decades of experience in medical devices, robotics, and life sciences.
Latest Features
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
More News
29 May 2025 Novo Nordisk faces resistance from Connecticut clinic in Ozempic and Wegovy dispute | LIVation admits to referencing Novo Nordisk products in past marketing but it has since been removed | Clinic claims its compounded semaglutide use was lawful and clear to patients.
29 May 2025 Shilpa Medicare failed to prove invalidity of patent covering Lenvima | Eisai says ruling keeps India-based generic maker’s product off the market until 2036.
27 May 2025 Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic company hoped to stay proceedings to prepare appeal against unfavourable decision.
27 May 2025 UPC rejects jurisdictional challenges from Moderna | Court allows two linked infringement cases over mRNA tech to move forward in The Hague | Ruling finds commercial links between Moderna entities enough to justify its jurisdiction over non-UPC territories.
22 May 2025 Artificial intelligence is undoubtedly impacting the biotech lifecycle, and presents myriad applications—and risks. Tim Powell, Vishnu Shankar and Ben Rowlatt of Morgan Lewis provide a detailed analysis.
22 May 2025 AstraZeneca subsidiary Alexion suffers setback in bid to stop rivals launching biosimilars of blood disorder drug | Ruling concerns an error in original patent application | Decision follows UPC defeat for Alexion over eculizumab patent.
22 May 2025 South Korean company eyes new business opportunities following Supreme Court ruling | Pfizer had claimed infringement of patent covering Prevenar 13 shot.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox